GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » 3-Year EBITDA Growth Rate

Diamyd Medical AB (OSTO:DMYD B) 3-Year EBITDA Growth Rate : 0.00% (As of Nov. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB 3-Year EBITDA Growth Rate?

Diamyd Medical AB's EBITDA per Share for the three months ended in Nov. 2024 was kr-0.31.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Diamyd Medical AB was 11.20% per year. The lowest was -123.40% per year. And the median was 2.20% per year.

Competitive Comparison of Diamyd Medical AB's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Diamyd Medical AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's 3-Year EBITDA Growth Rate falls into.


;
;

Diamyd Medical AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Diamyd Medical AB  (OSTO:DMYD B) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Diamyd Medical AB 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
OSTO:BINV OSTO:EGTX OSTO:HNSA OSTO:GENO OSTO:VICO OSTO:XSPRAY OSTO:SYNACT OSTO:SANION OSTO:IRLAB A OSTO:ABLI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
DMN:Germany
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Website
https://www.diamyd.com
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines